Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats

Hormone and Metabolic Research

Volumn 36, Issue 3, 2004, Pages 183-187

  Chen, A S ^a   Taguchi, T ^a   Sugiura, M ^a   Wakasugi, Y ^a   Kamei, A ^a   Wang, M W ^b   Miwa, I ^a  

^a MEIJO UNIVERSITY   (Japan)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Aminoguanidine; Antioxidant activity; Diabetic cataract; Diabetic neuropathy; Glycation; Pyridoxal aminoguanidine adduct

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALKENE; AMINOGUANIDINE; BIOLOGICAL MARKER; DNA; DRINKING WATER; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LIPID; MALONALDEHYDE; PYRIDOXAL; PYRIDOXAL AMINOGUANIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; CATARACT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE COURSE; DISEASE MARKER; DNA DAMAGE; GLUCOSE BLOOD LEVEL; GLYCATION; HEMOGLOBIN DETERMINATION; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; LIVER LEVEL; MALE; MOTOR NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RAT; STREPTOZOCIN DIABETES; TIME; TREATMENT OUTCOME; URINALYSIS; URINE VOLUME;

ANIMALS; CATARACT; DEOXYGUANOSINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; GUANIDINES; HEMOGLOBIN A, GLYCOSYLATED; LENS, CRYSTALLINE; LIPID PEROXIDATION; LIVER; MALE; MOTOR NEURONS; NEURAL CONDUCTION; PYRIDOXAL; RATS; RATS, WISTAR; TIME FACTORS;

ANIMALIA;

EID: 1942472961     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-814344     Document Type: Article

References (27)

1. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-267
2. van Dam PS. Oxidative stress and diabetic neuropathy: pathophysiological mechanism and treatment perspectives. Diabetes Metab Res Rev 2002; 18: 176-184
3. Edelstein D, Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992; 41: 26-29
4. Picard S, Parthasarathy S, Fruebis J, Witztum JL. Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 1992; 89: 6876-6880
5. Giardino I, Fard AK, Hatchell DL, Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 1998; 47: 1114-1120
6. Philis-Tsimikas A, Parthasarathy S, Picard S, Palinski W, Witztum JL. Aminoguanidine has both pro-oxidant and antioxidant activity toward LDL. Arterioscler Thromb Vasc Biol 1995; 15: 367-376
7. Skamarauskas JT, McKay AG, Hunt JV. Aminoguanidine and its prooxidant effects on an experimental model of protein glycation. Free Radic Biol Med 1996; 21: 801-812
8. Taguchi T, Sugiura M, Hamada Y, Miwa I. In vivo formation of a Schiff base of aminoguanidine with pyridoxal phosphate. Biochem Pharmacol 1998; 55: 1667-1671
9. Taguchi T, Sugiura M, Hamada Y, Miwa I. Inhibition of advanced protein glycation by a Schiff base between aminoguanidine and pyridoxal. Eur J Pharmacol 1999; 378: 283-289
10. Miyoshi H, Taguchi T, Sugiura M, Takeuchi M, Yanagisawa K, Watanabe Y, Miwa I, Makita Z, Koike T. Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephrophathy in mice. Horm Metab Res 2002; 34: 371-377
11. +)-ATPase activity reduction in high glucose-treated human erythrocytes. Free Radic Biol Med 2001; 30: 232-237
12. 6 and N-acetylcysteine: its possible relevance to cataract formation in diabetes. Free Radic Biol Med 2002; 33: 1615-1621
13. Kato K, Nakayama K, Ohta M, Murakami N, Murakami K, Mizota M, Miwa I, Okuda J. Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur J Pharmacol 1991; 193: 185-191
14. Ansari NH, Bhatnagar A, Fulep E, Khanna P, Srivastava SK. Trolox protects hyperglycemia-induced cataractogenesis in cultured rat lens. Res Commun Chem Pathol Pharmacol 1994; 84: 93-104
15. Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 1991; 88: 6107-6111
16. Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K. Effect of amino-guanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 1992; 41: 47-52
17. Cameron NE, Cotter MA, Dines K, Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin- diabetic rats. Diabetologia 1992; 35: 946-950
18. Miyauchi Y, Shikama H, Takasu T, Okamiya H, Umeda M, Hirasaki E, Ohhata I, Nakayama H, Nakagawa S. Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozotocin-induced diabetic rats. Eur J Endocrinol 1996; 134: 467-473
19. Dewhurst M, Omawari N, Tomlinson DR. Aminoguanidine-effects on endoneurial vasoactive nitric oxide and on motor nerve conduction velocity in control and streptozotocin-diabetic rats. Br J Pharmacol 1997; 120: 593-598
20. +)-ATPase activity and thrombomodulin expression in streptozotocin-induced diabetic rats. Diabetologia 1999; 42: 743-747
21. Swamy-Mruthinti S, Green K, Abraham EC. Inhibition of cataracts in moderately diabetic rats by aminoguanidine. Exp Eye Res 1996; 62: 505-510
22. Agardh E, Hultberg B, Agardh C-D. Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats. Curr Eye Res 2000; 21: 543-549
23. Azal Ö, Yönem A, Güler S, Çakir A, Baydar A, Çorakçi A, Kutlu M. Effects of aminoguanidine and tolrestat on the development of ocular and renal structural changes in experimental diabetic rats. Diab Obes Metab 2002; 4: 75-79
24. Edelstein D, Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992; 41: 26-29
25. Jain SK, Palmer M. The effect of oxygen radicals metabolites and vitamin E on glycosylation of proteins. Free Radic Biol Med 1997; 22: 593-596
26. Ross WM, Creighton MO, TrevithickJR, Stewart-DeHaan JP, Sanwal M. Modelling cortical cataractogenesis IV. Induction by glucose in vitro or in diabetic rats: prevention and reversal by glutathione. Exp Eye Res 1983; 37: 559-573
27. Srivastava SK, Ansari NH. Prevention of sugar-induced cataractogenesis in rats by butylated hydroxytoluene. Diabetes 1988; 37: 1505-